Dean Rudge
Senior Reporter
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
Small Cash Component Delaying Opioid Deal, Says ‘Optimistic’ Teva
Teva CEO Kåre Schultz has spoken at great length and in great detail about Teva’s ability to reach a proposed settlement in the US over allegations the firm helped fuel the opioid epidemic, revealing that a deal may be only 12 months away.
Teva Likes Biosimilar Licensing Deals As It Cuts Full-Year Sales Guidance
Teva is keeping a keen eye out for opportunities like its US biosimilars agreement with Alvotech and more recent deal with Bioeq for biosimilar Lucentis as it attempts to maintain revenues in the coming years, following a cut to full-year sales guidance for 2021.
US Court Dismisses Viatris EpiPen Suit, But Further Action Possible
US pharmacy KPH Healthcare Services, acting on behalf of purchasing giant McKesson, has seen an antitrust suit filed against Viatris’ Mylan and Pfizer dismissed, although the court said it would allow plaintiffs to come back with a further complaint.
Takeda Prevacid Suit Was Not A ‘Sham,’ US Court Tells Zydus Cadila
A US district court has denied Zydus Cadila’s motion for summary judgment on Sherman Act antitrust counterclaims against Takeda over a branded formulation of lansoprazole, finding that the originator did have basis to sue the ANDA sponsor again in 2018.
Jubilant To Reorganize With Generics API Business On The Move
Jubilant Pharmova – formerly Jubilant Life Sciences – plans to separate and move the active pharmaceutical ingredient business currently in the hands of its generic pharmaceuticals subsidiary, taking eventual control of the business itself.
UK Vaccines Business Pushes Wockhardt To Sales Growth
Having a year ago radically altered its business by offloading operations in India to rival Dr Reddy’s, India’s Wockhardt saw another burst of sales in the UK, amid its tie-up with AstraZeneca for the COVID-19 vaccine.